65,437 trials
Dental Plaque
Primary: Gingival Index — 1.90; 1.84 Units on a scale — p=0.005
Respiratory Failure
Primary: Number of Participants With Successful Extubation, Reintubation and in Hospital Mortality — 28; 29; 3; 3 participants — p=>0.05
Healthy
Primary: Maximal Plasma Concentration (Cmax) — 2,503.04; 2,496.88; 1,706.03 pg/mL
Attention Deficit Disorder With Hyperactivity
Primary: Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Score at Up to 5 Weeks — -15.93; -16.03; -18.51; -8.51 Units on a Scale…
Colorectal Neoplasms
Primary: Time to Progression (TTP) at Primary Completion: FOLFIRI and mIFL — 8.18; 6.01 months — p=0.0152
Cervical Cancer · Genital Warts
Primary: Incidence of the Composite Endpoint of Human Papillomavirus (HPV) 16/18-related Cervical Intraepithelial Neoplasia (CIN) 2 or Worse in the Base Study — 0.0; 0.4…
Stomach Neoplasms
Primary: Best Overall Response — 0; 2; 25; 42 participants
Actinic Keratosis
Primary: Number of Participants With 100% Clearance of Actinic Keratosis Lesions: Comparison of Taro Imiquimod 5% and Aldara-Imiquimod 5% — 63; 54 Participants
Abdominal Cancer
Primary: Time to First Postoperative Flatus in Days Was the End of Postoperative Ileus (POI) Indicator. — 3.16; 3.88 Days — p=<0.05
ADHD
Primary: Change From Baseline in the Oppositional Subscale of the Conners' Parent Rating Scale-Revised Long Form (CPRS-R:L) Score at Up to 8 Weeks — -10.8; -7.0 Units on a scale…
Ovarian Cancer · Neoplasms, Ovarian
Primary: Number of Participants With the Indicated Response — 6; 11; 20; 7 participants
Anemia, Sickle Cell
Primary: Wechsler Adult Intelligence Scale (WAIS)-III Performance IQ — 90.6; 95.9 Points on a scale — p=0.008
Attention Deficit Disorder With Hyperactivity
Primary: Change From Baseline in the Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Total Score at 6 Weeks — -17.8; -13.8 Units on a Scale — p=<0.0001
Pulmonary Disease, Chronic Obstructive
Primary: Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) 2 Hours Post-dose of Blinded Study Drug — 155; 150 milliliters (mL) — p=0.021
Healthy
Primary: Maximum Plasma Concentration (Cmax) of Rosiglitazone — 0.41; 0.43 ug/mL